Search For a Provider Facebook Twitter Instagram YouTube ES View the Patient Toolkit

Conditions: HSDD

Addyi: Information for Healthcare Providers

Addyi: Information for Healthcare ProvidersAs a health professional, you’ve most likely heard about the FDA’s approval of Addyi (flibanserin), a drug used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. You may even have had patients ask you about it already. Indeed, it is a big step for women’s sexual health. Before Addyi, women with HSDD did not have many treatment options.

However, Addyi isn’t to be taken lightly. With the approval, the FDA requires a risk evaluation and mitigation strategy (REMS) to ensure that Addyi is prescribed and dispensed correctly.

Addyi is expected to go on the market by October 17, 2015. In our latest blog post, we go over some common questions and answers on Addyi geared to patients. Here, we’d like to discuss some issues that healthcare providers should know about.


1 2 3 4 Next » (page 1 of 4)

Related Stories